Taking it

Taking saquinavir (Invirase) with low dose ritonavir boosts the amount of saquinavir in the blood and ensures saquinavir stays in the body for longer. Various doses of ritonavir (Norvir)-boosted saquinavir have been tested in clinical trials, but in September 2002, European drug regulatory authorities approved twice daily saquinavir at a dose of 1000mg with 100mg ritonavir. This dose was approved in the United States in December 2003.

Ritonavir-boosted saquinavir should be taken within two hours of a meal. Saquinavir and ritonavir should be taken at the same time in order to ensure that saquinavir concentrations are boosted adequately. Saquinavir should only be used with ritonavir or with ritonavir-boosted lopinavir.

Saquinavir is available both in 200mg capsules, and in new 500mg tablets. The two formulations produce similar levels of active drug in the blood, and both require ritonavir boosting and need to be taken with food.1 However, use of the tablet formulation reduces the number of pills that a patient needs to take every day.

Saquinavir should not be the only protease inhibitor in an antiretroviral combination. Without ritonavir boosting, less than 10% of each dose is absorbed into the bloodstream and very small quantities cross into the central nervous system. The antiviral effects of hard gel saquinavir-based combinations are significantly smaller and less sustained than those of combinations based on other protease inhibitors, unless it is taken in combination with another protease inhibitor such as ritonavir.

Saquinavir at a dose of 400mg boosted by 400mg ritonavir twice a day is also approved, but this dosage is less popular due to its greater frequency of side-effects.2 One study has also shown than once-daily ritonavir at 100mg can still boost saquinavir levels when taken twice a day. This may help to reduce the pill burden and side-effects associated with ritonavir boosting, but it causes reductions in saquinavir exposure relative to twice-daily ritonavir, and cannot be recommended.3

Once-daily dosing of ritonavir-boosted saquinavir has also been studied in trials. Doses of 1600mg saquinavir with 100 or 200mg ritonavir are effective and produce adequate drug exposure.4 5 6 However, further research is required before this approach can be recommended.

Saquinavir should not be taken by patients with severe liver impairment.

References

  1. Bittner B et al. Saquinavir 500 mg film-coated tablets demonstrate bioequivalence to saquinavir 200 mg hard capsules when boosted with twice-daily ritonavir in healthy volunteers. Antivir Ther 10: 803-810, 2005
  2. Gisolf E et al. The effect of treatment intensification in HIV-infection: a study comparing treatment with ritonavir / saquinavir and ritonavir / saquinavir / stavudine. Prometheus Study Group. AIDS 14: 405-413, 2000
  3. Boffito M et al. Boosted saquinavir hard gel formulation exposure in HIV-infected subjects: ritonavir 100mg once daily versus twice daily. J Antimicrob Chemother 55: 542-545, 2005
  4. Ananworanich J et al. Pharmacokinetics of once-daily saquinavir hard gel caps with saquinavir soft gel caps boosted with ritonavir in HIV+ Thai patients. 14th International AIDS Conference, Barcelona, abstract MoPeB2007, 2002
  5. Ananworanich J et al. A prospective cohort study of efficacy and safety of 2 NRTIs plus once-daily ritonavir-boosted saquinavir hard gel capsule (SQV-HGC / r) at 24 weeks. 15th International AIDS Conference, Bangkok, abstract TuPeB4469, 2004
  6. Autar RS et al. Pharmacokinetic study of saquinavir hard gel caps / ritonavir in HIV-1-infected patients: 1600 / 100 mg once-daily compared with 2000 / 100 mg once-daily and 1000 / 100 twice-daily. J Antimicrob Chemother 54: 785-790, 2004
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.